Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer

New England Journal of Medicine

Volumn 366, Issue 4, 2012, Pages 299-309

  Von Minckwitz, Gunter ^a   Eidtmann, Holger ^b   Rezai, Mahdi ^c   Fasching, Peter A ^d   Tesch, Hans ^e   Eggemann, Holm ^f   Schrader, Iris ^g   Kittel, Kornelia ^h   Hanusch, Claus ^k   Kreienberg, Rolf ^l   Solbach, Christine ^m   Gerber, Bernd ⁿ   Jackisch, Christian ^o   Kunz, Georg ^p   Blohmer, Jens Uwe ⁱ   Huober, Jens ^t   Hauschild, Maik ^q   Fehm, Tanja ^r   Müller, Berit Maria ^j   Denkert, Carsten ^j   Loibl, Sibylle ^a   Nekljudova, Valentina ^a   Untch, Michael ^s   more..

^a Headquarters   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Luisenkrankenhaus   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e Bethanien Krankenhaus Frankfurt   (Germany)

^f UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^g Henrietten Stiftung   (Germany)

^h Onkologische Praxis   (Germany)

ⁱ MARTIN LUTHER KRANKENHAUS   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k Klinikum Zum Roten Kreuz   (Germany)

^l UNIVERSITY HOSPITAL ULM   (Germany)

^m UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁿ ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^o Klinikum Offenbach GmbH   (Germany)

^p ST JOHANNES HOSPITAL   (Germany)

^q Frauenklinik   (Germany)

^r UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^s Helios Klinikum   (Germany)

^t CANTONAL HOSPITAL ST GALLEN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; HORMONE RECEPTOR; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING DISORDER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TUMOR VOLUME;

EID: 84856291930     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1111065     Document Type: Article

References (24)

1. von Minckwitz G, Untch M, Nüesch E, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011;125:145-56.
2. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85.
3. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010;28:2024-31.
4. Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011; 29:3351-7.
5. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377-84.
6. Huober J, von Minckwitz G, Denkert C, et al. Effect of neoadjuvant anthracyclinetaxane- based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010;124:133-40.
7. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
8. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol (in press).
9. von Minckwitz G, Kümmel S, Vogel P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008;100:542-51.
10. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
11. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47.
12. Robert NJ, Diéras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252-60.
13. Li CY, Shan S, Huang Q, et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 2000; 92:143-7. (Pubitemid 30089871)
14. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer, 2010.
15. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer, 1980. (IARC scientific publications no. 32.)
16. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:2676-85. (Pubitemid 46179457)
17. von Minckwitz G, Eidtmann H, Loibl S, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer: safety results of the GeparQuinto trial. Ann Oncol 2011;22:301-6.
18. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:102-15.
19. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005;102:3738-43. (Pubitemid 40354681)
20. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012;366:310-20.
21. Bear HD, Tang G, Rastogi P, et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol 2011;29:Suppl:1005. abstract.
22. Miller K, Christmon D, Perkins S, et al. A pilot study of vascular endothelial growth factor inhibition with bevacizumab in patients with lymphedema following breast cancer treatment. J Clin Oncol 2009; 27:Suppl:488s. abstract.
23. Golshan M, Garber JE, Gelman R, et al. Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol 2011;18:733-7.
24. Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011;29:83-8.